ArticleProbiotics and antimicrobial proteins2019
More Protection of Lactobacillus acidophilus Than Bifidobacterium bifidum Probiotics on Azoxymethane-Induced Mouse Colon Cancer.
Article in Probiotics and antimicrobial proteins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review on the role of the gut microbiota in tumors and their treatment.Frontiers in endocrinology · 2024Pooled it
- Preclinical Evidence of Probiotics in Colorectal Carcinogenesis: A Systematic Review.Digestive diseases and sciences · 2020Pooled it
- Novel targets in rectal cancer by considering lncRNA-miRNA-mRNA network in response to Lactobacillus acidophilus consumption: a randomized clinical trial.Scientific reports · 2022Trial
- Oral Lactobacillus reuteri Combined With Intravenous Lysis-Circuit-Bearing Engineered Bacteria RE Enhances Antitumor Efficacy.Biotechnology journal · 2026Article
- The Potential Anticancer Mechanisms of Probiotics: A Comprehensive Review.Probiotics and antimicrobial proteins · 2026Review
- Article
- Serum CA19-9 and CEA levels, serum CAT, GSH, oxidised glutathione levels, 8-dihidro-2'-deoksiguanosina and F2-isoprostanes levels in colorectal cancer patients and Lactobacillus: A randomised double-blind controlled trial.Journal of medical biochemistry · 2025Article
- Application and Challenges of Using ProbioticDiseases (Basel, Switzerland) · 2025Review
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Advances in research on the intestinal microbiota in the mechanism and prevention of colorectal cancer (Review).Molecular medicine reports · 2025Review
- Modulating Gut Microbiota with Dietary Components: A Novel Strategy for Cancer-Depression Comorbidity Management.Nutrients · 2025Review
- Article
- The oncobiome; what, so what, now what?Microbiome research reports · 2025Review
- Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer.Medical oncology (Northwood, London, England) · 2024Review
- Article
- Study on the effect and mechanism ofFrontiers in microbiology · 2024Article
- Review
- Article
- An Update on the Pivotal Roles of Probiotics, Their Components, and Metabolites in Preventing Colon Cancer.Foods (Basel, Switzerland) · 2023Review
- Chemopreventive effect of a milk whey by-product derived from Buffalo (Bubalus bubalis) in protecting from colorectal carcinogenesis.Cell communication and signaling : CCS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the ability of the probiotics in the gut microflora modification, they can have the beneficial effects on diseases in the short and/or the long term. In previous study, we revealed that unlike Bifidobacterium bifidum, the amount of Lactobacillus acidophilus remained almost unchanged in mice gut microflora in the long term, indicating more stability of L. acidophilus than B. bifidum which can be used to prevent some incurable diseases such as cancer. Thirty-eight male BALB/c mice were divided into four groups, control, azoxymethane (AOM), L. acidophilus, and B. bifidum probiotics, to evaluate the protective effects of the probiotics on AOM-induced mouse colon cancer. Except for the control group, the rest of the animals were weekly given AOM (15 mg/kg, s.c) in three consecutive weeks. Colon lesion incidence was 74% in the AOM group in comparison with the control (0%) (P < 0.05). The lesions were varied from mild to severe dysplasia and colonic adenocarcinoma. Administration of the probiotics inhibited the incidence of colonic lesions by about 57% in L. acidophilus (P < 0.05) and 27% in B. bifidum (P > 0.05) compared to the AOM group. The serum levels of CEA and CA19-9 tumor markers were significantly decreased in L. acidophilus in comparison with the AOM group (P < 0.05). Moreover, the serum levels of IFN-γ and IL-10 and the number of CD4
Indexed as
Identifiers
29682678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.